Jiangsu Hengrui Medicine (SHA:600276, HKG:1276) obtained approval for Hetrombopag Olamine Tablets for adding a new indication from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The approved indication is for use of the product in combination with immunosuppressive therapy for patients aged 15 years and older with treatment-naive severe aplastic anemia (SAA).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments